ALNYLAM PHARMACEUTICALS, INC. (ALNY) FY2026 Q2 Balance Sheet

ALNYLAM PHARMACEUTICALS, INC. (ALNY) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets

5,558,769,000 US dollars

Current assets

4,620,172,000 US dollars

Non-current assets

938,597,000 US dollars

Liabilities

4,204,651,000 US dollars

Current liabilities

1,512,513,000 US dollars

Non-current liabilities

2,692,138,000 US dollars

Equity

1,354,118,000 US dollars

Cash and cash equivalents

1,708,318,000 US dollars

Marketable debt securities

1,599,829,000 US dollars

Accounts receivable, net

912,739,000 US dollars

Prepaid expenses and other current assets

302,176,000 US dollars

Inventory

97,110,000 US dollars

Property, plant and equipment, net

554,143,000 US dollars

Operating lease right-of-use assets

183,359,000 US dollars

Deferred tax assets

113,792,000 US dollars

Other assets

65,132,000 US dollars

Restricted investments

22,171,000 US dollars

Accrued expenses

1,095,980,000 US dollars

Liabilities related to the sale of future royalties and development funding

258,570,000 US dollars

Accounts payable

108,016,000 US dollars

Operating lease liabilities

45,933,000 US dollars

Deferred revenue

4,014,000 US dollars

Liabilities related to the sale of future royalties and development funding, net of current portion

1,461,510,000 US dollars

Convertible debt

1,010,981,000 US dollars

Operating lease liabilities, net of current portion

210,495,000 US dollars

Other liabilities

9,152,000 US dollars

Additional paid-in capital

7,716,958,000 US dollars

Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025

1,337,000 US dollars

Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025

0 US dollars

Accumulated deficit

negative 6,332,039,000 US dollars

Accumulated other comprehensive loss

negative 32,138,000 US dollars

Gross equity (calculated)

7,718,295,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.